Francisco Perez Clavijo
Foot & Ankle Surgery · Doral, FLNPI 1366447625
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $10,143 of the $13,262 with a category attached, or 76.5%. It is spread thinly across 23 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $4,190 and has fallen 77.0% since, to $965 in 2025.
Across 170 payments — averaging $78.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$3K
- Royal Biologics, Inc.$2K
- Musculoskeletal Transplant Foundation Inc.$2K
- Smith+Nephew$1K
- AbbVie$1K
- Shockwave Medical, Inc$1K
- plus $2K from 17 others
Across 25 payments — averaging $5254.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Smith+Nephew$87K
- Osiris Therapeutics Inc.$43K
- Integra Lifesciences Corporation$2K
What the payments were for
- Consulting fees$1,60012%
- Travel & lodging$1,35610%
- Food & beverage$10,14376%
- Entertainment$1631%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 39 | $2,882 |
| Royal Biologics, Inc. | 7 | $2,445 |
| Musculoskeletal Transplant Foundation Inc. | 17 | $1,838 |
| Smith+Nephew | 33 | $1,454 |
| AbbVie | 38 | $1,164 |
| Shockwave Medical, Inc | 8 | $1,087 |
| Anika Therapeutics, Inc. | 3 | $873 |
| Stryker | 2 | $248 |
| Osiris Therapeutics Inc. | 4 | $238 |
| Innovation Technologies Inc | 1 | $135 |
| Bard Peripheral Vascular, Inc. | 1 | $125 |
| Nevro Corp. | 1 | $121 |
| Boston Scientific | 1 | $121 |
| GSK | 1 | $119 |
| Cardiovascular Systems Inc. | 1 | $115 |
| KCI USA, Inc. | 3 | $89 |
| Acera Surgical, Inc. | 3 | $58 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Stimwave Technologies Incorporated | 1 | $32 |
| Paratek Pharmaceuticals, Inc. | 1 | $24 |
| GRT US Holding, Inc. | 1 | $24 |
| Kerecis Limited | 1 | $23 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CryoCord$1,496
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$1,087
- TACTOSET$873
- Fibrinet$800
- Stravix$499
- PuraPly AM$461
- DALVANCE$362
- Grafix$362
- GrafixPL$362
- PuraPly$328
- Apligraf$282
- SIMPLIMAX$207
- AmnioMaxx$149
- GRAFIX PL$137
- Irrisept$135
- VENOVO$125
- SALVATION$125
- INFINITY$123
- Omnia$121
- GENERAL VASCULAR INTERVENTION$121
How this compares
$13,262 in reported general payments places this provider in the 80th percentile of 850 foot & ankle surgery providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SantylCollagenase Clostridium Hist. | 14 | $4,832 |
| Ciclopirox | 141 | $3,165 |
| Clotrimazole | 60 | $2,508 |
| Ammonium Lactate | 69 | $1,198 |
| Ketoconazole | 70 | $1,128 |
| Nystatin | 11 | $412 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $124 |
| CiclopiroxCiclopirox Olamine | 16 | $114 |
| Mupirocin | 14 | $113 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Smith+NephewSantyl | $1,454 | $4,83214 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 850 foot & ankle surgery providers in Florida.
Other foot & ankle surgery in Doral
- Thomas SangiovanniCoral Gables$2.1M
- Shayne JensenPanama City$1.3M
- Thomas RoukisOrlando$1M
- Craig BreslauerStuart$971K
- Bradley LammWest Palm Beach$861K
- Amber ShaneOrlando$830K
- Jonathan BlumKissimmee$785K
- Mario CalaHialeah$541K
- Christopher ReevesLake Mary$424K
- Ettore VulcanoMiami Beach$411K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.